8-K5.02
EDGARLician Pro · $19.99/mo or $149/yr · AAPL vs MSFT
Vertex Pharmaceuticals Inc (VRTX) SEC filings
Vertex Pharmaceuticals Inc (VRTX) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.
Those exhibit numbers sit next to the income-statement cache: Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7. The VRTX filings page is the source view; the stock page is the research view.
EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Vertex Pharmaceuticals Inc said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.
Recent filings
8-K1.017.018.01
EDGARVRTX SEC filings FAQ
What is the latest VRTX SEC filing?
The latest cached Vertex Pharmaceuticals Inc (VRTX) filing on this page is 8-K · Sep 1, 2026. Filings: https://lician.com/sec/vrtx
What is the latest VRTX filing accession number?
The latest cached Vertex Pharmaceuticals Inc (VRTX) accession number on this page is 0000875320-26-000264. Filing: https://lician.com/sec/vrtx/0000875320-26-000264
Which item code is on the latest VRTX filing?
Cached item code on the latest Vertex Pharmaceuticals Inc (VRTX) 8-K is 5.02.
How many VRTX SEC filings are listed on this page?
This page lists 2 cached Vertex Pharmaceuticals Inc (VRTX) SEC filings. Filings: https://lician.com/sec/vrtx
What is VRTX's P/E ratio?
Vertex Pharmaceuticals Inc (VRTX) trailing P/E is 29.7 on the latest cached fundamentals snapshot.
What are VRTX's latest revenue and net income?
Latest cached Vertex Pharmaceuticals Inc (VRTX) revenue for Dec 31, 2025 was $12.00B. Net income was $3.95B. Statements: https://lician.com/financials/vrtx